Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Legend Biotech (LEGN) over the last 6 years, with Dec 2024 value amounting to $1.7 billion.

  • Legend Biotech's Liabilities and Shareholders Equity fell 1.32% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 billion, marking a year-over-year decrease of 6.55%. This contributed to the annual value of $1.7 billion for FY2024, which is 9.65% down from last year.
  • As of FY2024, Legend Biotech's Liabilities and Shareholders Equity stood at $1.7 billion, which was down 9.65% from $1.8 billion recorded in FY2023.
  • In the past 5 years, Legend Biotech's Liabilities and Shareholders Equity registered a high of $1.8 billion during FY2023, and its lowest value of $722.1 million during FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.6 billion, with a median of $1.7 billion in 2024.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first spiked by 150.98% in 2020, then declined by 9.65% in 2024.
  • Legend Biotech's Liabilities and Shareholders Equity (Yearly) stood at $722.1 million in 2020, then spiked by 55.03% to $1.1 billion in 2021, then increased by 18.89% to $1.3 billion in 2022, then skyrocketed by 38.89% to $1.8 billion in 2023, then dropped by 9.65% to $1.7 billion in 2024.